跳至主要内容
临床试验/CTRI/2019/05/018884
CTRI/2019/05/018884已完成未知

Oral Acetazolamide for Antipsychotic induced weight gain â?? An open label study

Anupama Priyamkari0 个研究点目标入组 34 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
已完成
发起方
入组人数
34

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Out patients or in patients diagnosed as schizophrenia, schizoaffective disorder, delusional disorder, psychosis NOS, Non organic psychosis diagnosed using MINI PLUS
  • Both males and females
  • 18 â?? 60 years of age
  • Patients who are treated with Risperidone or Olanzepine
  • Patients who are drug naïve, off medication for atleast 6 months or have been on psychotropic medications for less than 1 month.
  • Without any co-morbid psychiatric illness other than nicotine use

排除标准

  • Persons on Acetazolamide for any medical reasons.
  • No known medical conditions in which acetazolamide is contraindicated like hyperchloremic acidosis, hypokalaemia, hyponatremia, adrenal insufficiency, impaired kidney function, hypersensitivity to acetazolamide or other sulphonamides, liver diseases.
  • Pregnancy, lactation
  • Sub normal intelligence

研究者

发起方
Anupama Priyamkari

相似试验